慢性腰痛市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類別、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球慢性腰痛市場預計將從 2025 年的 24.8 億美元成長到 2031 年的 40.8 億美元，複合年成長率達到 8.65%。

此領域涵蓋多種藥物療法、介入性醫療設備和復健服務，旨在治療持續12週或更長時間的疼痛。推動該領域發展的關鍵因素包括全球人口老化導致脊髓退化風險增加，以及久坐不動的生活方式加劇了肌肉骨骼健康問題。此外，全球肥胖率的上升也給腰椎帶來了巨大的機械壓力，從而持續催生了對有效且永續的疼痛管理方案的需求，而這些方案並非依賴暫時性的緩解措施。

然而，由於為應對全球對成癮和濫用問題的擔憂，各國對鴉片類藥物處方實施了嚴格的監管，市場面臨巨大的挑戰。這種監管限制了傳統藥物治療方法的潛在患者群體，並加速了對更昂貴的非鴉片類替代療法的需求。世界衛生組織（世衛組織）強調了這個問題的迫切性，在2024年發布的報告中指出，背痛影響著全球約6.19億人，是全球主要的殘疾原因之一。

市場促進因素

隨著醫療保健系統尋求更安全的傳統鎮痛藥替代方案，向非鴉片類療法和生物製藥的策略性轉變正在從根本上改變市場格局。這種轉變推動了創新疼痛訊號抑制劑和標靶生物製藥的研發，這些藥物能夠為神經病變脊髓疾病患者提供持續緩解，並避免了鴉片類藥物固有的依賴性風險。例如，2024年12月，Vertex Pharmaceuticals公司宣布，其舒澤曲因（suzetrigine）的II期臨床試驗結果顯示，在腰薦神經根病患者中，患者在數字疼痛評分量表（NPS）上的平均疼痛評分顯著降低了2.02分。這表明，對於不適合手術或對非類固醇抗發炎藥物（NSAIDs）無反應的患者而言，下一代治療方案具有巨大潛力。

同時，在微創手術技術的進步以及神經刺激和植入式疼痛管理設備日益普及的推動下，市場持續成長。製造商正在加速將封閉回路型感測技術應用於脊髓刺激（SCS）系統，從而實現即時調整，提高患者依從性和治療效果。作為這項進展的佐證，Saluda Medical於2024年12月宣布，其EVA感測技術已獲得美國食品藥物管理局（FDA）的核准。該技術透過掃描脊髓來最佳化刺激參數。鑑於問題的嚴重性，此類創新至關重要。根據美國疾病管制與預防中心（CDC）2024年的報告，24.3%的美國成年人在過去一年中經歷過慢性疼痛，凸顯了對可擴展設備解決方案的巨大需求。

市場挑戰

圍繞鴉片類藥物處方的嚴格法規結構是全球慢性下背痛市場成長的主要障礙。這些旨在降低患者成癮和濫用風險的法規，直接限制了鴉片類鎮痛藥的銷售，而鴉片類鎮痛藥歷來是其主要收入來源。製藥公司面臨著巨大的市場准入障礙和日益嚴格的審查，導致新治療方法的核准和商業化進程延緩。因此，出於法律責任的考慮，醫療機構正在減少處方量，這導致傳統疼痛治療方法市場萎縮，並造成重症患者的治療缺口。

這些法規的影響因需要有效治療的背痛發生率不斷上升而進一步加劇。市場陷入兩難：一方面，緩解疼痛的需求日益成長；另一方面，強效藥物的供應受到法律限制。為了進一步說明背痛給職業健康帶來的沉重負擔，美國國家安全委員會指出，到2024年，背痛將成為最常見的肌肉骨骼疾病，其參與機構中有77.3%報告了背痛病例。這項統計數據凸顯了在現有監管限制下，緩解疼痛的需求與市場供應能力之間日益擴大的差距。

市場趨勢

基於虛擬實境（VR）的數位療法的引入，透過提供身臨其境型居家干預，從生物學、心理學和社會學的角度解決慢性下背痛問題，從而開創了一種新的治療模式。這些系統利用虛擬環境重新訓練疼痛處理通路，為患者提供擴充性的、無藥物的替代方案。 AppliedVR於2024年12月發表的一項大型臨床試驗的二次分析證實了該方法的有效性。在完成RelieVRx計畫後，70%的高影響慢性疼痛患者被重新歸類為低影響疼痛，這表明自我管理的數位療法可以在改善患者預後的同時，減輕醫療負擔。

同時，人工智慧驅動的診斷工具的引入正在透過自動化影像數據分析和確保診斷一致性，徹底改變脊椎醫學。機器學習演算法正被用於解讀腰椎MRI影像，其檢測退化性疾病的可靠性遠超過人工方法。北美放射學會於2024年11月宣布舉辦年度人工智慧挑戰賽，全球共有1874支隊伍參與，共同開發用於檢測腰椎退化性疾病的模型，充分體現了該領域的蓬勃發展。這項進展將使臨床醫生能夠更有效地對患者進行分層，並治療性介入。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球慢性腰痛市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物分類（非類固醇消炎劑、抗憂鬱症、鎮痛藥、鴉片類藥物、其他）
  • 給藥途徑（口服、外用、其他）
  • 分銷通路（醫院藥局、零售/線上藥局、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美慢性腰痛市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲慢性腰痛市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區慢性腰痛市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲慢性腰痛市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲慢性腰痛市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球慢性腰痛市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• ProMed Pharma LLC
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson
• Medtronic Plc
• Endo Pharmaceuticals Inc
• Sanofi SA
• Boston Scientific Corporation
• Vertos Medical, Inc.
• Astellas Pharma Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Chronic Lower Back Pain Market is projected to expand from USD 2.48 Billion in 2025 to USD 4.08 Billion by 2031, achieving a CAGR of 8.65%. This sector comprises a wide range of pharmacotherapies, interventional medical devices, and rehabilitation services aimed at treating pain that persists for more than twelve weeks. Growth is primarily driven by an aging global population prone to spinal degeneration, alongside the prevalence of sedentary lifestyles that worsen musculoskeletal health. Furthermore, increasing obesity rates worldwide impose greater mechanical stress on the lumbar spine, generating a consistent demand for effective, enduring pain management solutions that do not rely on temporary fixes.

However, the market confronts substantial obstacles due to strict regulations on opioid prescriptions, which are enforced to address global concerns regarding addiction and abuse. This regulatory scrutiny restricts the potential patient base for traditional pharmacological treatments and accelerates the need for more expensive non-opioid alternatives. The urgency of this issue is highlighted by the World Health Organization, which reported in 2024 that low back pain impacts approximately 619 million people globally, establishing it as the leading cause of disability worldwide.

Market Driver

A strategic pivot toward non-opioid pharmacological therapies and biologics is fundamentally transforming the market as healthcare systems seek safer alternatives to traditional analgesics. This shift is driving the creation of innovative pain signal inhibitors and targeted biologics capable of providing lasting relief for neuropathic spinal conditions without the addiction risks inherent to opioids. For example, Vertex Pharmaceuticals announced in December 2024 that its Phase 2 study of suzetrigine showed a statistically significant mean reduction of 2.02 points on the numeric pain rating scale for patients with lumbosacral radiculopathy, demonstrating the potential of these next-generation treatments for patients unsuitable for surgery or unresponsive to NSAIDs.

Concurrently, the market is expanding through the adoption of neurostimulation and implantable pain management devices, bolstered by advances in minimally invasive surgical techniques. Manufacturers are increasingly incorporating closed-loop sensing into spinal cord stimulation (SCS) systems, enabling real-time adjustments that improve patient compliance and outcomes. As evidence of this progress, Saluda Medical announced in December 2024 that the U.S. FDA approved its EVA sensing technology, which scans the spinal cord to optimize stimulation parameters. These innovations are critical given the scale of the issue; the Centers for Disease Control and Prevention reported in 2024 that 24.3% of U.S. adults had experienced chronic pain in the prior year, highlighting the massive demand for scalable device solutions.

Market Challenge

Rigorous regulatory frameworks governing opioid prescriptions constitute a major barrier to the growth of the Global Chronic Lower Back Pain Market. These regulations, implemented to mitigate global risks of patient dependency and abuse, directly limit the sales of opioid-based analgesics, which have traditionally been a core revenue source. Pharmaceutical companies encounter significant hurdles to market entry and increased surveillance, slowing the approval and commercialization of new therapies. Consequently, healthcare providers are reducing prescription rates due to liability concerns, thereby shrinking the addressable market for conventional pain therapies and leaving a treatment gap for severe cases.

The impact of these restrictions is exacerbated by the rising incidence of back pain requiring effective management. The market is caught in a dichotomy where the demand for relief is intensifying while the supply of potent pharmacological interventions is legislatively restricted. Underscoring the extent of this occupational and health burden, the National Safety Council identified low back pain as the most common musculoskeletal ailment in 2024, reported by 77.3% of participating organizations. This statistic highlights a widening gap between the demand for relief and the market's ability to provide it under current regulatory constraints.

Market Trends

The incorporation of virtual reality-based digital therapeutics is creating a new paradigm by delivering immersive, home-based interventions that target the bio-psycho-social dimensions of chronic back pain. These systems employ virtual environments to retrain pain processing pathways, offering a scalable, drug-free alternative for patients. The efficacy of this approach was highlighted by AppliedVR in December 2024, where a secondary analysis of a major clinical trial revealed that 70% of patients with high-impact chronic pain were reclassified to lower-impact pain after completing the RelieVRx program, demonstrating that self-administered digital therapeutics can alleviate healthcare burdens while improving patient outcomes.

Simultaneously, the deployment of AI-driven diagnostic tools is revolutionizing spinal care by automating the analysis of imaging data to ensure consistent diagnoses. Machine learning algorithms are being utilized to interpret lumbar MRI scans, detecting degenerative conditions with greater reliability than manual methods. The intensity of development in this field was evident in November 2024, when the Radiological Society of North America reported that 1,874 global teams participated in its annual AI challenge to create models for detecting degenerative lumbar spine conditions. This advancement allows clinicians to stratify patients more effectively, ensuring that interventions are precisely targeted to individual pathologies.

Key Market Players

• ProMed Pharma LLC
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson
• Medtronic Plc
• Endo Pharmaceuticals Inc
• Sanofi SA
• Boston Scientific Corporation
• Vertos Medical, Inc.
• Astellas Pharma Inc.

Report Scope

In this report, the Global Chronic Lower Back Pain Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Lower Back Pain Market, By Drug Class

• Non-steroidal Anti-inflammatory Drugs
• Antidepressants
• Analgesic
• Opioids
• Others

Chronic Lower Back Pain Market, By Route of Administration

• Oral
• Topical
• Others

Chronic Lower Back Pain Market, By Distribution Channel

• Hospital Pharmacies
• Retail & Online Pharmacies
• Other

Chronic Lower Back Pain Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Lower Back Pain Market.

Available Customizations:

Global Chronic Lower Back Pain Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Lower Back Pain Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Non-steroidal Anti-inflammatory Drugs, Antidepressants, Analgesic, Opioids, Others)
  • 5.2.2. By Route of Administration (Oral, Topical, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Chronic Lower Back Pain Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chronic Lower Back Pain Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Chronic Lower Back Pain Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Chronic Lower Back Pain Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Chronic Lower Back Pain Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chronic Lower Back Pain Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Chronic Lower Back Pain Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Chronic Lower Back Pain Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Chronic Lower Back Pain Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Chronic Lower Back Pain Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Chronic Lower Back Pain Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Chronic Lower Back Pain Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Chronic Lower Back Pain Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Chronic Lower Back Pain Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Chronic Lower Back Pain Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Chronic Lower Back Pain Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Chronic Lower Back Pain Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Chronic Lower Back Pain Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Chronic Lower Back Pain Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Chronic Lower Back Pain Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Chronic Lower Back Pain Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Chronic Lower Back Pain Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Chronic Lower Back Pain Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Chronic Lower Back Pain Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Chronic Lower Back Pain Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ProMed Pharma LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc
• 15.3. Teva Pharmaceutical Industries Ltd.
• 15.4. Johnson & Johnson
• 15.5. Medtronic Plc
• 15.6. Endo Pharmaceuticals Inc
• 15.7. Sanofi SA
• 15.8. Boston Scientific Corporation
• 15.9. Vertos Medical, Inc.
• 15.10. Astellas Pharma Inc.

16. Strategic Recommendations

17. About Us & Disclaimer